Quick Links
Past Events

Credit Designation

Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity

Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 2.0 Contact Hours.


Not an official event of the 2017 ASCO Annual Meeting. Not sponsored or endorsed by ASCO or the Conquer Cancer Foundation.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from AstraZeneca.

Privacy Policy
Terms & Conditions
Executive Board
Faculty Portal
Google +
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
Physicians’ Education Resource ®, LLC.
All rights reserved.

Evolving Applications of Immuno-Oncology Strategies: New Approaches, New Combination, and New Ways to Care for Lung, Head and Neck, and Bladder Cancers

Evolving Applications of Immuno-Oncology Strategies: New Approaches, New Combination, and New Ways to Care for Lung, Head and Neck, and Bladder Cancers

Saturday, June 3, 2017

Dinner and registration: 6:30PM - 7:00PM
Scientific Session: 7:00PM - 9:00PM

Hilton Chicago
International North Ballroom, Lobby Level
720 S Michigan Avenue
Chicago, IL 60605


Evolving Applications of Immuno-Oncology Strategies: New Approaches, New Combinations, and New Ways to Care for Lung, Head and Neck, and Bladder Cancers is a live symposium that will be held adjunct to the annual oncology meeting in Chicago. The emergence of immuno-oncology strategies to treat cancer has transformed the way clinicians think about solid tumor management. Among these tumors, lung cancer, head and neck cancer, and bladder cancer have become a major focus of investigational efforts in immuno-oncology research due to both substantial unmet clinical needs and evidence demonstrating the clinical potential of these approaches. In addition to single-agent immunotherapy, the use of novel immuno-oncology combinations is generating interest, and rational clinical trial designs are combining immunotherapy with a wide range of partner therapeutics, with the goal of inducing profound and durable responses. Further, the speed at which information continues to emerge in the immuno-oncology space is creating practice and/or educational gaps for oncology clinicians who strive to maintain state-of-the-art care for their patients. To address these educational needs, this symposium also will feature internationally renowned experts in immuno-oncology who will discuss key emerging clinical data sets, the role of evolving biomarkers, and how to safely apply immunotherapy to a wide variety of malignancies.

Key topics to be addressed by faculty include:

  • Practice-changing data with immunotherapy in lung, head and neck, and bladder cancers
  • Current approaches to biomarkers and patient selection
  • Recognizing and managing unique adverse events with immunotherapy
  • Emerging data with new immunotherapy approaches

The symposium will be held at the Hilton Chicago on June 3, 2017, from 7:00 PM-9:00 PM. Please join us learn about the latest immuno-oncology approaches that you can apply in your clinical practice. This is a symposium not to be missed!

Target Audience:

This educational activity is directed toward medical oncologists. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of cancer are also invited to participate.

Learning Objectives:

Upon completion of this activity, participants will be better prepared to:

  • Detail specific anti–CTLA-4, anti–PD-1, and anti–PD-L1 mechanistic approaches in the context of their developmental rationale to target solid tumors
  • Apply evidence on single agent/combination immuno-oncology strategies and explain its impact on decision-making in the evolving fields of lung cancer, head and neck squamous cell cancer (HNSCC), and bladder cancer
  • Delineate practical methods to individualize the application of immuno-oncology strategies based on PD-L1 testing results
  • Develop multidisciplinary actions steps to proactively mitigate the impact of immune-related adverse events among patients who receive checkpoint inhibitors for the treatment of non–small cell lung cancer, HNSCC, and bladder cancer

Activity Chair

Roy S. Herbst, MD, PhD
Ensign Professor of Medicine (Medical Oncology)
Professor of Pharmacology
Chief of Medical Oncology
Associate Director for Translational Research
Yale Cancer Center, Smilow Cancer Hospital
New Haven, CT

Become a Member

Forgot Password?
Calendar of Events
Filter By